Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global sedation in ICU setting market size reached a value of around USD 3.16 billion in 2023. The market is expected to grow at a CAGR of 5.60% during the forecast period of 2024-2032 to attain a value of USD 5.15 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
A state of serenity, relaxation, or sleepiness brought on by medicines is referred to as sedation. During medical or surgical procedures, sedation may be used to help people cope with severely stressful situations or to reduce anxiety. In the ICU setting, sedative drugs are frequently used primarily to alleviate agitation and anxiety, which can be brought on by a variety of different diseases.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on drug class, the market is segmented into propofol, benzodiazepines, dexmedetomidine, and remifentanil, among others. The regional markets for sedation in ICU setting can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global sedation in ICU setting market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.
Based on drug class, the market was dominated by propofol in the historical period. During the forecast period, the segment is expected to dominate the sedation in ICU setting market. This occurs as a result of propofol's rapid uptake as a painkiller and agitation suppressant in mechanical breathing. In the upcoming years, this will help propofol's market expansion, along with the introduction of generic products.
In order to sedate patients in the ICU, propofol is frequently given as a continuous intravenous infusion. Propofol has special qualities that allow it to penetrate the blood-brain barrier quickly, which causes sedation to start working quickly. Additionally, coronavirus (COVID-19) patients in the intensive care unit (ICU) who require mechanical breathing may be sedated with propofol.
It is anticipated that North America will dominate the global sedation in ICU setting market. This is because of the increasing older population with comorbid illnesses and increasing number of beds for critical care in developed countries like Canada and the United States. The region's expansion is also being fuelled by the rise in infectious disorders including sepsis and respiratory conditions that require ICU hospitalisation.
Growing hospital ICUs, expanding healthcare infrastructure, and an increase in ICU admissions are some of the key drivers of the global sedation in ICU setting market in developing nations in the Asia Pacific and Latin American regions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Medtronic plc, founded in 1949 is a leading manufacturer of medical equipment and treatments, including pacemakers, insulin pumps, and treatments for diabetes. It is best recognised for its ground-breaking cardiac devices, including pacemakers that are battery-operated and small. However, it has also put cutting-edge technologies into the market.
AstraZeneca plc, a holding company with its headquarters in the United Kingdom is involved in the creation, production, and research of pharmaceutical goods. To treat diseases in the cancer, cardiovascular, infection, neurological, respiratory, gastrointestinal, and inflammatory domains, the business develops, produces, and sells pharmaceutical and biotechnology products.
GlaxoSmithKline plc, one of the biggest research-based pharmaceutical firms in the world is headquartered in England and produces, promotes, and distributes products for human health. For the purpose of preventing and treating disease, it creates novel vaccinations and specialised medications.
Other market players include Mylan N.V., Teva Pharmaceutical Industries Ltd., and B. Braun Medical, among others.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Class |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
In 2023, the global market for sedation in ICU setting attained a value of nearly USD 3.16 billion.
The market for sedation in ICU setting is projected to grow at a CAGR of 5.60% during the forecast period of 2024-2032.
The sedation in ICU setting market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach USD 5.15 billion by 2032.
The major drivers of the market include the increasing patient pool, increasing investment towards improvement of healthcare facilities, rise in disposable income of people, rising number of critical care beds in the developed nations, growing number of hospitals ICUs and rising ICU admissions.
A rise in geriatric population and increasing cases of comorbid diseases are the key trends propelling the growth of the market.
The major regions in the sedation in ICU setting market are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
The major players in the market include Medtronic plc, AstraZeneca plc, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., and B. Braun Medical, among others.
The benzodiazepines midazolam and lorazepam (and to a lesser extent, diazepam), the short-acting intravenous anaesthetic propofol, and dexmedetomidine are sedatives that are frequently used in the ICU. The sedative properties of the opioid remifentanil led to its usage as a single agent.
Some patients require long-term sedation, perhaps for weeks. The anaesthetic will often be turned off once the issue for which they were admitted to the ICU has been resolved so they can be evaluated. The breathing tube may be removed if they are performing well.
In order to maximise ventilator synchronisation and lessen any discomfort associated with critical illness, patients who were mechanically ventilated in the ICU were traditionally kept thoroughly sedated with ongoing depressive infusions.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share